1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Translating Disruptive New Approach Methodologies (NAMs) into Practice is sponsored by European Commission — Horizon Europe. Expected Impact: This Challenge supports ambitions to maintain and strengthen the health sector in Europe. It will: Accelerate the development and validation of disruptive NAMs for biomedical applications, including medicinal products and medical technologies Support regulatory innovation by providing evidence-based recommendations for the assessment of safety, efficacy, and quality of human health products using NAMs. Enable citizens to benefit from novel technologies that have been assessed through rigorous NAMs that have been validated to can predict potential effects in humans, and Provide industry with a harmonised and standardised NAM-based assessment toolkit that is faster and more flexible. Objective: Specific Objectives This is a two-stage Challenge competition with the ultimate ambition to deliver robust, validated NAMs that constitute a representative model or prototype system i.e. achieve TRL 6 after Stage 2. Applicants should apply to Stage 1 only where there is an outlook of the potential impact in the longer term. Stage 1 – Solution validation and benchmarking Applicants should: Take forward preliminary engagement with regulatory authorities, notified bodies and industry stakeholders Map regulatory, clinical, standardisation (where applicable) and industrial needs, and use this to develop a roadmap for adoption Develop a methodology for performance assessment Deliver small-scale feasibility experiments or modelling Conduct initial performance benchmarking (human relevance, reproducibility, transferability of the approach) Assess ethical, data governance and scalability considerations, as applicable to the given NAM under development. The following milestones need to be achieved at the end of Stage 1: Evidence that the NAM is viable for human relevant biomedical innovation, and addresses the needs of the identified use cases, and Clear commitment from industrial end-users and a well-defined regulatory plan to further develop the NAM in Stage 2. Progress to Stage 2 will be contingent on delivering a full proposal which will be assessed alongside the milestones achieved under Stage 1. Stage 2 – Development and user testing Applicants selected for Stage 2 will further develop and validate a functional, scalable NAM prototype ready for regulatory, industrial, or clinical uptake. Activities must cover a number of the following elements: Benchmarking the NAMs against state-of-the-art animal models and/or human trials Demonstration in relevant application, such as disease modelling, or testing of medicinal products and medical technologies for safety, efficacy, or quality Organisation of consultation meetings/workshops with industrial end users, regulators, CROs (Contract Research Organisations), standard setting bodies or other relevant stakeholders to gather further needs and feedback Engagement with infrastructures for testing and data collection as testing and validation of the NAM outside the developer’s lab Development of regulatory-grade data packages suitable for submission to relevant agencies (e.g. EMA, FDA, OECD), and Documentation on scalability, standardisation, and potential barriers to uptake. During the project’s implementation phase, beneficiaries will be encouraged to consider using the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) of the European Commission’s Joint Research Centre for aspects of standardisation, automation and validation of in vitro methods. These facilities operate and provide support at the interface between pre-normative research, regulatory sciences and innovation. Scope: New Approach Methodologies (NAMs) have the potential to replace, reduce or refine animal use in the testing96 of medicinal products. Scientific progress in recent decades has delivered several animal-free NAMs that have the potential to transform how we understand human biology and assess the safety, efficacy, and quality testing in the health sector. However, a lack of knowledge, experi
Programme areas: Additional EIC activities, The European Innovation Council (EIC), Innovative Europe
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
EU Funding & Tenders Portal EU Funding & Tenders Portal * Results & Innovation support * SME Self-assessment tool Home Funding Calls for proposals Translating Disruptive New Approach Methodologies (NAMs) into Practice Translating Disruptive New Approach Methodologies (NAMs) into Practice * Conditions and documents EIC Advanced Innovation Challenge (HORIZON-EIC-2026-AIC) HORIZON-EIC HORIZON EIC Grants HORIZON Lump Sum Grant [HORIZON-AG-LS] 26 February 2026 17:00:00 Brussels time This Challenge supports ambitions to maintain and strengthen the health sector in Europe.
It will: * Accelerate the development and validation of disruptive NAMs for biomedical applications, including medicinal products and medical technologies * Support regulatory innovation by providing evidence-based recommendations for the assessment of safety, efficacy, and quality of human health products using NAMs.
* Enable citizens to benefit from novel technologies that have been assessed through rigorous NAMs that have been validated to can predict potential effects in humans, and * Provide industry with a harmonised and standardised NAM-based assessment toolkit that is faster and more flexible.
This is a two-stage Challenge competition with the ultimate ambition to deliver robust, validated NAMs that constitute a representative model or prototype system i.e. achieve TRL 6 after Stage 2. Applicants should apply to Stage 1 only where there is an outlook of the potential impact in the longer term.
**Stage 1 – Solution validation and benchmarking** * Take forward preliminary engagement with regulatory authorities, notified bodies and industry stakeholders * Map regulatory, clinical, standardisation (where applicable) and industrial needs, and use this to develop a roadmap for adoption * Develop a methodology for performance assessment * Deliver small-scale feasibility experiments or modelling * Conduct initial performance benchmarking (human relevance, reproducibility, transferability of the approach) * Assess ethical, data governance and scalability considerations, as applicable to the given NAM under development.
The following milestones need to be achieved at the end of Stage 1: * Evidence that the NAM is viable for human relevant biomedical innovation, and addresses the needs of the identified use cases, and * Clear commitment from industrial end-users and a well-defined regulatory plan to further develop the NAM in Stage 2.
Progress to Stage 2 will be contingent on delivering a full proposal which will be assessed alongside the milestones achieved under Stage 1. **Stage 2 – Development and user testing** Applicants selected for Stage 2 will further develop and validate a functional, scalable NAM prototype ready for regulatory, industrial, or clinical uptake.
Activities must cover a number of the following elements: * Benchmarking the NAMs against state-of-the-art animal models and/or human trials * Demonstration in relevant application, such as disease modelling, or testing of medicinal products and medical technologies for safety, efficacy, or quality * Organisation of consultation meetings/workshops with industrial end users, regulators, CROs (Contract Research Organisations), standard setting bodies or other relevant stakeholders to gather further needs and feedback * Engagement with infrastructures for testing and data collection as testing and validation of the NAM outside the developer’s lab * Development of regulatory-grade data packages suitable for submission to relevant agencies (e.g. EMA, FDA, OECD), and * Documentation on scalability, standardisation, and potential barriers to uptake.
During the project’s implementation phase, beneficiaries will be encouraged to consider using the EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) of the European Commission’s Joint Research Centre for aspects of standardisation, automation and validation of in vitro methods. These facilities operate and provide support at the interface between pre-normative research, regulatory sciences and innovation.
New Approach Methodologies (NAMs) have the potential to replace, reduce or refine animal use in the testing96 of medicinal products. Scientific progress in recent decades has delivered several animal-free NAMs that have the potential to transform how we understand human biology and assess the safety, efficacy, and quality testing in the health sector.
However, a lack of knowledge, experience and confidence in the use of such novel methodologies has limited their adoption by end users, including, for example, industry and regulators. This Challenge competition therefore looks to accelerate the adoption of NAMs in biomedicine and support companies that want to bring NAMs to the market.
Applicants should propose innovative and disruptive NAMs addressing one or both of the following areas: * Preclinical biomedical research * Testing of medicinal products and medical technologies for safety, efficacy, or quality.
Human organoids or microphysiological systems (e.g. organ-on-chip, disease-on-chip), in chemico methods, digital twins, virtual patient simulations, AI-enhanced predictive models, mechanistic or integrated in silico platforms, 3D- advanced human tissue model are in scope.
Applicants to this Challenge call should already have: * Proven the viability of their proposed solution in a lab environment at TRL 4 (lab or in silico); * Have letters of intent of at least one of the following stakeholders: an industrial end-user or regulatory body interested in the proposed project; and * Have access to an appropriate infrastructure to carry out the planned activities in Stage 1 and 2.
Applicants to the HORIZON-EIC-2026-AIC-02 topic should note that, in accordance with the EIC 2026 Work Programme, a letter of intent from an industrial end-user or regulatory body is mandatory. Failure to include the required letter of intent will result in the proposal being declared inadmissible. Where appropriate, multiple letters may be submitted; all letters must be combined into a single PDF document annexed to Proposal Part B.
Ethics self-assessment should be included in proposal part A of the proposal. The character limited in this section of proposal part A is considered to be sufficient for participants to give all necessary information. No ethics annex to proposal part B is needed/possible.
The EIC Work Programme 2026 states that: “Sections 1 to 3 and the cover page of part B of your proposal must consist of a maximum of 11 format A4 pages. ” The application template states the same. There is no explicit need for a cover page.
The application can start with the title of the proposal as per the application template. The EIC FAQs have been updated on 23/01/2026. Please (re)consult the FAQs.
The submission session is now available for: HORIZON-EIC-2026-AIC-01, HORIZON-EIC-2026-AIC-02 Topic conditions and documents #### 1.
Admissibility Conditions: Proposal page limit and layout The call is open for submission by * A single legal entity established in a Member State or an Associated Country (‘mono-beneficiary’) if you are a start-up, SME or research performing organisation (university, research or technology organisation, including teams, individual Principal Investigators and inventors).
Larger companies (i.e. which do not qualify as SMEs) are not eligible to apply as a single legal entity. **Proposal page limits and layout:** described in Part B of the Application Form available in the Submission System. #### 2.
Eligible Countries The list of eligible countries is detailed in Annex 2 of the EIC Work Programme 2026. #### 3. Financial and operational capacity and exclusion Described in Annex 2(C.
Financial and Operational Capacity) of the EIC Work Programme 2026. #### 4. Legal and financial set-up of the grants Please refer to the Model Grant Agreement (MGA) used for EIC actions under Horizon Europe Specific conditions are described in the section IV.
EIC Advanced Innovation Challenges- Pilot of the EIC Work Programme 2026 #### Additional documents: EU Financial Regulation 2024/2509 Decision authorising the use of lump sum contributions under the Horizon Europe Programme Decision authorising the use of lump sums for the EIC Advanced Innovation Challenges pilot phase 1 actions Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment EU Grants AGA — Annotated Model Grant Agreement Funding & Tenders Portal Online Manual Funding & Tenders Portal Terms and Conditions Funding & Tenders Portal Privacy Statement | Topic | Budget (EUR) - Year : 2026 | Stages | Opening date | Deadline | Contributions | Indicative number of grants | | --- | --- | --- | --- | --- | --- | --- | | HORIZON-EIC-2026-AIC-01 - HORIZON-EIC HORIZON EIC Grants HORIZON-EIC-2026-AIC-02 - HORIZON-EIC HORIZON EIC Grants | 6 000 000 | Single-stage | 03/12/2025 | 26/02/2026 | around 300000 around 300000 | 10 10 | To access the Electronic Submission Service, please click on the submission-button next to the **type of action** and the **type of model grant agreement** that corresponds to your proposal.
You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point. To access existing draft proposals for this topic, please login to the Funding & Tenders Portal and select the My Proposals page of the My Area section.
**Please select the type of your submission:** HORIZON EIC Grants [HORIZON-EIC], HORIZON Lump Sum Grant [HORIZON-AG-LS] Topic Q&As**0** item(s) found Please read carefully all provisions below before the preparation of your application. EIC Frequently Asked Questions – FAQ on the Europen Innovation Council website specific to the Advanced Innovation Challenges topics.
Online Manual is your guide on the procedures from proposal submission to managing your grant. Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe. Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular. National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’).
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding. IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc. European IPR Helpdesk assists you on intellectual property issues.
CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal. The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.
Partner Search help you find a partner organisation for your proposal.
XFacebookLinkedinTelegram **EU Funding & Tenders Portal** **Single Electronic Data Interchange Area (SEDIA)** _This site is managed by: Directorate-General for Research and Innovation_ Information about the EU Funding & Tenders PortalInformation about the EU funding & me app Calls for tenders on TedOverview of all EU funding opportunitiesAccess to publications and data on OpenAIREApply for EU loans & venture capitalFind funding in the EU Macro-RegionsPublish in Open Research Europe (Open Access)Public list of entities excluded or subject to financial penalty - EDES Database
According to the current listing, eligibility includes: Open to legal entities established in EU Member States and countries associated to Horizon Europe (including EEA/EFTA countries, and other associated third countries). Action type: HORIZON-EIC HORIZON EIC Grants. Additional conditions: "> General conditions 1. Admissibility Conditions: Proposal page limit and layout The call is open for submission by A single legal entity established in a Member State or an Associated Country (‘mono-beneficiary’) if you are a start-up, SME or research performing organisation (university, research or technology organisation, including teams, individual Principal Investigators and inventors). Larger companies (i.e. which do not qualify as SMEs) are not eligible to apply as a single legal... See the official call documentation on the F&T Portal for full eligibility criteria and participation rules. Confirm the full requirements in the official notice before applying.
The current listing shows €12M total budget (~$13M USD) ; up to €300K per project ; ~10 grants expected. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was February 26, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Translating Disruptive New Approach Methodologies (NAMs) into Practice is funded by European Commission — Horizon Europe. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Reinforcing EU autonomous access to space through EU-based spaceports is sponsored by European Commission — Horizon Europe. Expected Outcome: Project results are expected to contribute to all of the following outcomes: Reinforcing EU strategic autonomy by reducing non-EU dependencies for accessing space; Providing an EU access to space necessary for EU space missions through state of the art and innovative solutions; Diversifying the access to space providers in the EU; Contributing to expand commercial access to space offers and services in the EU; Reinforcing Access to Space to ensure that Europe maintains and improve autonomous, reliable and cost-effective access to space. Scope: The EU needs to improve the resilience of its access to space for the implementation of EU space programme. New entrants will contribute to this endeavour. Projects are expected to support EU launch service providers to set up launch pad(s) in the EU territory enabling to perform EU launch services. Projects are expected to contribute to the development of necessary ground facilities to conduct launch services from the EU territory; e.g. launch integration, storage and operation facilities, launch pad and complex, control command facility, payload processing and integration facilities, tracking means, safety means, propellant storage... EU launch service provider(s) are expected to be part of the project consortium and be the ultimate users of the resulting facilities making use of EU launch vehicles for providing EU launch services. Proposals under this topic should explore synergies and be complementary to past actions related to ground segment for launch services, in particular the topics: HORIZON-CL4-2023-SPACE-01-23 and HORIZON-CL4-2025-02-SPACE-11. All the activities should be complementary with national and ESA on-going or future activities, in particular those decided at the ESA council Ministerial Meeting in November 2025. In this topic, the integration of the gender dimension (sex and gender analysis) in research and innovation content should be addressed only if relevant in relation to the objectives of the research effort. Technology Readiness Level - Technology readiness level expected from completed projects Activities are expected to achieve TRL 8 by the end of the project. The reference TRL definition is the ISO 16290:2013 applicable to the space sector. Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Digital, Industry and Space
Space critical Equipment for EU non-dependence – Space Refuelling Interface is sponsored by European Commission — Horizon Europe. Expected Outcome: Project results are expected to contribute to all of the following expected outcomes: Reinforcing EU strategic autonomy by reducing non-EU dependencies on critical space Equipment and related technologies across their entire supply chain; Providing unrestricted access to critical space Equipment and related technologies relevant for EU space missions and pilots (e.g. In-Orbit Space Operations); Developing or regaining capacity to operate independently in space by developing resilient space Equipment and related technologies supply chains, relying on EU supply chains and/or trustable and reliable supply chains not affected by non-EU export restrictions; Enhancing competitiveness by developing products and capabilities reaching equivalent or superior performance level than those from outside the EU and compete at worldwide level. Scope: Unrestricted access to state-of-art space equipment and related technologies is a pre-requisite for the EU space industry responding to EU space missions. However, especially for some families of equipment, the available solutions in EU do not meet the current high-performance space requirements. Currently, alternative products sourced from outside EU, are either affected by non-EU export control, that limits its use, or present challenges in terms of trustable supply chains for the implementation of EU space missions with a security dimension. Within the frame of this topic, it is expected to finance and implement a development project aiming at maturing critical equipment with the final goal of lowering the dependency from outside EU. This will be done by establishing a long-term sustainable supply chain for supporting EU strategic autonomy in the space sector. The selection of the supply chains shall reflect this objective. Therefore, the supply chain shall preferably be built fully based in EU and when this can only be achieved partially, services procured from outside EU shall nevertheless ensure that the overall supply chain will remain trustable and not affected by non-EU export control. The latest scenario is subject to the approval of the granting authority (i.e. DG-DEFIS and HaDEA). The space equipment and related technologies relevant for this topic represent a direct implementation of the EU Observatory of Critical Technologies (OCT) Technology Roadmap, named Robotics Manipulators for Space Applications: Space Refuelling Interface . Further details will be provided at the latest at the opening of the Call, in a Guidance document published on the Funding & Tenders Portal. Space is a low volume market affected by a dynamic industrial landscape compared to the terrestrial market therefore, technological spin in and/or bilateral collaborations should be enhanced between European non-space and space industries. Furthermore, proposed activities should be complementary to relevant national or other activities at EU level. Complementary activities should be clearly identified, described and the proposal should report how the complementarity is ensured. To achieve the non-dependence objective, applicants are expected to include a dedicated proposal’s paragraph covering: The description of the technology and/or technology processes used for developing the equipment and high-level breakdown of the supply chain to be used. Applicants should demonstrate that the supply chain and final product are free of any legal export restrictions or limitations, such as those established in the International Traffic in Arms Regulations (ITAR) or equivalent instruments applicable in other non-EU jurisdictions. Applicants shall also report, in a dedicated subsection, if and which part of the supply chain is affected by non-EU export controls such as the Export Administration regulation (EAR) i.e. EAR99. The description of the suitable technology development process that has been identified and set up within the consortium for avoiding export restrictions of non-EU states and assess vulnerab Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Digital, Industry and Space, Space, including Earth Observation
IA Resilience call reinforcing Europe's strenght in health is sponsored by European Commission — Horizon Europe. Expected Outcome: the proposals under this call are expected to address one or more of the following subjects : • Enhanced personalized monitoring, care and treatments, focusing on the development of highly customized healthcare solutions, including the required research and diagnostic tools, tailored to individual needs, covering various scenarios such as chronic disease management, physiotherapy, precision diagnosis, personalized medicine/treatment, pre- and postoperative care, and daily assistance in homes and common spaces. It also targets effective management of chronic diseases and elderly care through personalized monitoring and interventions facilitated by advanced sensor technologies and edge-to-cloud solutions. This includes the development and integration of solutions for Hospitalization at Home, enabling patients to receive complex, remotely supervised care using intelligent medical devices capable of sensing, analysing, and transmitting real-time data. This requires a continuum, from in-hospital diagnostics to robust, long-term patient support at home via AI-driven care pathways and hospitalization at home. • Prevention and treatment of diseases, allowing the improved scientific understanding, early detection and proactive prevention of diseases through scientific research, continuous monitoring, predictive analytics, and timely alerts, possibly powered by AI algorithms. This preventive approach enables early intervention and significantly reduces risks associated with many illnesses such as viral infections (e.g. epi- and pan demics), cardiovascular diseases, diabetes complications affecting the health of the young and old. • Efficient, scalable, and cost-effective healthcare, demonstrating how ECS-based technologies can streamline clinical workflows, reduce administrative burdens, and improve resource allocation in healthcare systems. This includes automation and intelligent operations management across clinical, diagnostic, and homecare settings, ultimately improving cost-effectiveness and scalability. • Secure and compliant healthcare continuum, including solutions that ensure robust data protection and regulatory compliance (e.g. GDPR), particularly in handling sensitive health data. Projects should adopt privacy-by-design principles and implement secure data handling architectures using localized edge computing, encryption, authentication, and anonymization strategies within both clinical and assisted living environments. • Seamless interoperability across devices, systems, and platforms, addressing the integration of heterogeneous systems across the edge-to-cloud continuum. Solutions should rely on open standards and modular architectures to ensure interoperability, flexibility, and adaptability across various healthcare settings and use cases, fostering a unified European health-tech ecosystem. Programme areas: Horizon Europe (HORIZON), Global Challenges and European Industrial Competitiveness, Digital, Industry and Space
The EU's last major Horizon Europe work programme puts €14B on the table through 2027. A strategic breakdown of budgets, deadlines, eligibility, and how US-based teams can compete.
Read articleEUR 307M in Horizon Europe AI calls closed April 15, 2026. US researchers can participate — but the rules are specific. Here is how to navigate them.
Read articleThe EU committed €900 million to lure researchers with relocation grants worth up to €2 million each. France placed 41 of 46 recruits from the US. Here is what the global talent war means for American research institutions and grant seekers.
Read article